Barry A Borlaug1, Vojtech Melenovsky2, Katlyn E Koepp2. 1. From the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN. borlaug.barry@mayo.edu. 2. From the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN.
Abstract
RATIONALE: Abnormalities in nitric oxide signaling play a pivotal role in heart failure with preserved ejection fraction (HFpEF). Intravenous sodium nitrite, which is converted to nitric oxide in vivo, improves hemodynamics in HFpEF, but its use is limited by the need for parenteral administration. Nitrite can also be administered using a novel, portable micronebulizer system suitable for chronic use. OBJECTIVE: Determine whether inhaled nitrite improves hemodynamics in HFpEF. METHODS AND RESULTS: In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF (n=26) underwentcardiac catheterization with simultaneous expired gas analysis at rest and during exercise before and after treatment with inhaled sodium nitrite (90 mg) or placebo. The primary end point was the pulmonary capillary wedge pressure during exercise. Before study drug administration, HFpEF subjects displayed an increase in pulmonary capillary wedge pressure with exercise from 20±6 to 34±7 mm Hg (P<0.0001). After study drug administration, exercise pulmonary capillary wedge pressure was substantially improved by nitrite as compared with placebo (baseline-adjusted mean 25±5 versus 31±6 mm Hg; analysis of covariance P=0.022). Inhaled nitrite reduced resting pulmonary capillary wedge pressure (-4±3 versus -1±2 mm Hg; P=0.002), improved pulmonary artery compliance (+1.5±1.1 versus +0.6±0.9 mL/mm Hg), and decreased mean pulmonary artery pressures at rest (-7±4 versus -3±4 mm Hg; P=0.007) and with exercise (-10±6 versus -5±6 mm Hg; P=0.05). Nitrite reduced right atrial pressures, with no effect on cardiac output or stroke volume. CONCLUSIONS: Acute administration of inhaled sodium nitrite reduces biventricular filling pressures and pulmonary artery pressures at rest and during exercise in HFpEF. Further study is warranted to evaluate chronic effects of inhaled nitrite in HFpEF. CLINICAL TRIAL REGISTRATION: This single center randomized clinical trial is registered at clinicaltrials.gov (NCT02262078).
RCT Entities:
RATIONALE: Abnormalities in nitric oxide signaling play a pivotal role in heart failure with preserved ejection fraction (HFpEF). Intravenous sodium nitrite, which is converted to nitric oxide in vivo, improves hemodynamics in HFpEF, but its use is limited by the need for parenteral administration. Nitrite can also be administered using a novel, portable micronebulizer system suitable for chronic use. OBJECTIVE: Determine whether inhaled nitrite improves hemodynamics in HFpEF. METHODS AND RESULTS: In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF (n=26) underwent cardiac catheterization with simultaneous expired gas analysis at rest and during exercise before and after treatment with inhaled sodium nitrite (90 mg) or placebo. The primary end point was the pulmonary capillary wedge pressure during exercise. Before study drug administration, HFpEF subjects displayed an increase in pulmonary capillary wedge pressure with exercise from 20±6 to 34±7 mm Hg (P<0.0001). After study drug administration, exercise pulmonary capillary wedge pressure was substantially improved by nitrite as compared with placebo (baseline-adjusted mean 25±5 versus 31±6 mm Hg; analysis of covariance P=0.022). Inhaled nitrite reduced resting pulmonary capillary wedge pressure (-4±3 versus -1±2 mm Hg; P=0.002), improved pulmonary artery compliance (+1.5±1.1 versus +0.6±0.9 mL/mm Hg), and decreased mean pulmonary artery pressures at rest (-7±4 versus -3±4 mm Hg; P=0.007) and with exercise (-10±6 versus -5±6 mm Hg; P=0.05). Nitrite reduced right atrial pressures, with no effect on cardiac output or stroke volume. CONCLUSIONS: Acute administration of inhaled sodium nitrite reduces biventricular filling pressures and pulmonary artery pressures at rest and during exercise in HFpEF. Further study is warranted to evaluate chronic effects of inhaled nitrite in HFpEF. CLINICAL TRIAL REGISTRATION: This single center randomized clinical trial is registered at clinicaltrials.gov (NCT02262078).
Authors: Barry A Borlaug; Thomas P Olson; Carolyn S P Lam; Kelly S Flood; Amir Lerman; Bruce D Johnson; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2010-09-07 Impact factor: 24.094
Authors: Shashi Bhushan; Kazuhisa Kondo; David J Polhemus; Hiroyuki Otsuka; Chad K Nicholson; Ya-Xiong Tao; Hui Huang; Vasiliki V Georgiopoulou; Toyoaki Murohara; John W Calvert; Javed Butler; David J Lefer Journal: Circ Res Date: 2014-03-05 Impact factor: 17.367
Authors: Julian O M Ormerod; Sayqa Arif; Majid Mukadam; Jonathan D W Evans; Roger Beadle; Bernadette O Fernandez; Robert S Bonser; Martin Feelisch; Melanie Madhani; Michael P Frenneaux Journal: Circ Heart Fail Date: 2015-04-02 Impact factor: 8.790
Authors: Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Satyam Sarma; Douglas Stoller; Joseph Hendrix; Erin Howden; Justin Lawley; Sheryl Livingston; Beverley Adams-Huet; Courtney Holmes; David S Goldstein; Benjamin D Levine Journal: Circ Heart Fail Date: 2020-03-13 Impact factor: 8.790
Authors: Irene Cortés-Puch; Junfeng Sun; Alan N Schechter; Steven B Solomon; Ji Won Park; Jing Feng; Cameron Gilliard; Charles Natanson; Barbora Piknova Journal: Nitric Oxide Date: 2019-07-09 Impact factor: 4.427
Authors: Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug Journal: Eur Heart J Date: 2018-08-07 Impact factor: 29.983
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: Kara S Hughan; Andrea Levine; Nicole Helbling; Steven Anthony; James P DeLany; Maja Stefanovic-Racic; Bret H Goodpaster; Mark T Gladwin Journal: Hypertension Date: 2020-08-03 Impact factor: 10.190